• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

再次肺切除治疗第二原发性肺癌:发病率和生存率分析。

Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survival.

机构信息

Thoracic Surgery Department, Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris, Paris, France.

Paris 13 University, Sorbonne Paris Cité, Faculty of Medicine SMBH, Bobigny, France.

出版信息

Eur J Cardiothorac Surg. 2021 Jun 14;59(6):1287-1294. doi: 10.1093/ejcts/ezaa438.

DOI:10.1093/ejcts/ezaa438
PMID:33367556
Abstract

OBJECTIVES

Evaluating morbidity and survival of patients operated on for a second primary non-small-cell lung cancer (NSCLC).

METHODS

Retrospective collection of data from patients operated on for a second NSCLC between 2009 and 2018.

RESULTS

Fifty-two patients met the inclusion criteria. At the time of second pulmonary resection, the median time between the 2 surgeries was 25 months (5-44.5 months). Patients' median age was 65 years (61-68 years). Median tumour size was 16 mm (10-22 mm). Thoracoscopy was used in 75% of cases. The resection was a pneumonectomy (n = 1), bilobectomy (n = 1), lobectomy (n = 15), segmentectomy (n = 32) or wedge resection (n = 3). The length of stay was 7 days (5-9 days). Mortality was null and morbidity was 36.5%, mainly from grade I-II complications according to the Clavien-Dindo classification. The median follow-up was 28 months (13-50 months). The median overall survival was 67 months (95% confidence interval 60.8-73.1 months). Survival at 5 years and specific survival were 71.1% and 67.7%, respectively.

CONCLUSIONS

A second surgical resection of either synchronous or metachronous NSCLC has a morbidity that is not superior to the morbidity of the first operation. The new tumour is usually diagnosed at an early stage. An anatomical sublobar resection is most likely the best compromise. It might also be considered for the first operation when there is a suspicious synchronous lesion that may require surgery at a later stage.

摘要

目的

评估因第二原发性非小细胞肺癌(NSCLC)而行手术治疗患者的发病率和生存率。

方法

回顾性收集 2009 年至 2018 年间因第二原发性 NSCLC 而行手术治疗患者的数据。

结果

52 例患者符合纳入标准。在进行第二次肺切除时,两次手术之间的中位时间为 25 个月(5-44.5 个月)。患者的中位年龄为 65 岁(61-68 岁)。中位肿瘤大小为 16mm(10-22mm)。75%的病例采用了胸腔镜手术。切除方式为肺切除术(n=1)、双叶切除术(n=1)、肺叶切除术(n=15)、节段切除术(n=32)或楔形切除术(n=3)。住院时间为 7 天(5-9 天)。无死亡病例,发病率为 36.5%,主要为 Clavien-Dindo 分级的 I-II 级并发症。中位随访时间为 28 个月(13-50 个月)。中位总生存期为 67 个月(95%置信区间为 60.8-73.1 个月)。5 年生存率和特异性生存率分别为 71.1%和 67.7%。

结论

对同步或异时性 NSCLC 进行第二次手术切除的发病率并不高于第一次手术。新肿瘤通常在早期被诊断出来。解剖性亚肺叶切除术可能是最佳的折中方案。对于可能需要在后期手术的可疑同步病变,也可考虑在第一次手术时进行。

相似文献

1
Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survival.再次肺切除治疗第二原发性肺癌:发病率和生存率分析。
Eur J Cardiothorac Surg. 2021 Jun 14;59(6):1287-1294. doi: 10.1093/ejcts/ezaa438.
2
Pulmonary Resection for Second Lung Cancer After Pneumonectomy: A Population-Based Study.肺切除术后第二原发性肺癌的肺切除术:一项基于人群的研究。
Ann Thorac Surg. 2017 Oct;104(4):1131-1137. doi: 10.1016/j.athoracsur.2017.04.043. Epub 2017 Jul 12.
3
Second primary lung cancer and relapse: treatment and follow-up.第二原发性肺癌与复发:治疗与随访
Eur J Cardiothorac Surg. 1995;9(11):607-11. doi: 10.1016/s1010-7940(05)80104-6.
4
Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections.IA期非小细胞肺癌的肺叶下切除:肺段切除术相比楔形切除术,癌症相关生存率显著更高。
Eur J Cardiothorac Surg. 2008 Apr;33(4):728-34. doi: 10.1016/j.ejcts.2007.12.048. Epub 2008 Feb 7.
5
Additional pulmonary resections after pneumonectomy: actual long-term survival and functional results.肺切除术后的额外肺切除术:实际长期生存率和功能结果。
Eur J Cardiothorac Surg. 2008 Sep;34(3):493-8. doi: 10.1016/j.ejcts.2008.05.023. Epub 2008 Jun 25.
6
Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer?肺叶切除术在第二原发性肺癌的外科治疗中真的比亚肺叶切除术更有效吗?
Eur J Cardiothorac Surg. 2013 Aug;44(2):e120-5; discussion e125. doi: 10.1093/ejcts/ezt219. Epub 2013 May 8.
7
Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.临床ⅠA 期肺癌的长期结果:肺叶切除术与亚肺叶切除术比较。
Ann Thorac Surg. 2018 Aug;106(2):375-381. doi: 10.1016/j.athoracsur.2018.02.049. Epub 2018 Mar 23.
8
Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a Surveillance, Epidemiology, and End Results database analysis.亚肺叶切除术与老年T1a期非小细胞肺癌的肺叶切除术疗效相当:一项监测、流行病学和最终结果数据库分析
J Surg Res. 2016 Feb;200(2):683-9. doi: 10.1016/j.jss.2015.08.045. Epub 2015 Sep 3.
9
Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry.I 期非小细胞肺癌:波兰国家肺癌登记处肺叶切除术与亚肺叶切除术的长期结果。
Eur J Cardiothorac Surg. 2017 Aug 1;52(2):363-369. doi: 10.1093/ejcts/ezx092.
10
Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection.淋巴结清扫数目对接受亚肺叶切除术的Ⅰ期非小细胞肺癌患者生存的影响。
J Thorac Cardiovasc Surg. 2018 Jul;156(1):394-402. doi: 10.1016/j.jtcvs.2018.03.113. Epub 2018 Apr 4.

引用本文的文献

1
Repeated Anatomical Pulmonary Resection for Second Primary Nonsmall-Cell Lung Cancer: Safety and Short-Term Outcomes.复发性解剖性肺切除术治疗第二原发性非小细胞肺癌:安全性和短期疗效
Thorac Cancer. 2025 Jun;16(12):e70116. doi: 10.1111/1759-7714.70116.
2
Diagnosis and management of multiple primary lung cancer.多原发性肺癌的诊断与管理
Front Oncol. 2024 Oct 1;14:1392969. doi: 10.3389/fonc.2024.1392969. eCollection 2024.
3
The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy.
肺叶切除术后发生第二原发性非小细胞肺癌患者的临床组织学及预后特征
Interdiscip Cardiovasc Thorac Surg. 2023 Sep 2;37(3). doi: 10.1093/icvts/ivad155.
4
Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management-State of the Art.前线之外:胸外科医生在肺癌管理中的三线方法——最新进展
Cancers (Basel). 2023 Aug 9;15(16):4039. doi: 10.3390/cancers15164039.
5
A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients.一项比较原发性肺癌与第二原发性肺癌患者电视辅助胸腔镜手术成本差异及结果的回顾性分析。
Healthcare (Basel). 2023 Jun 14;11(12):1745. doi: 10.3390/healthcare11121745.
6
Feasibility and safety of secondary video-assisted thoracoscopic surgery for ipsilateral lung cancer after prior pulmonary resection.再次行电视辅助胸腔镜手术治疗同侧肺癌的可行性和安全性:肺切除术后。
Thorac Cancer. 2023 Jan;14(3):298-303. doi: 10.1111/1759-7714.14755. Epub 2022 Nov 30.
7
Outcome and prognosis of secondary lung cancer surgery with interstitial lung disease.伴间质性肺疾病的肺癌术后转归及预后。
Thorac Cancer. 2022 Jul;13(14):2024-2030. doi: 10.1111/1759-7714.14481. Epub 2022 May 30.
8
Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma.HLF 表达降低预示肺腺癌患者预后不良。
Med Sci Monit. 2021 May 12;27:e929333. doi: 10.12659/MSM.929333.